Evidence map›Paper›PMID 28356881›Full record

ArticleJournal of medical biochemistry2016

Association of GSTO1 and GSTO2 Polymorphism with Risk of End-Stage Renal Disease Development and Patient Survival.

Slavica Cimbaljevic, Sonja Suvakov, Marija Matic, Marija Pljesa-Ercegovac, Tatjana Pekmezovic, Tanja Radic, Vesna Coric, Tatjana Damjanovic, Nada Dimkovic, Rodoljub Markovic and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. TheMedicina (Kaunas, Lithuania) · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Slavica CimbaljevicSerbian Chamber of Biochemists.
Sonja SuvakovInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Marija MaticInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Marija Pljesa-ErcegovacInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tatjana PekmezovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tanja RadicInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Vesna CoricInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tatjana DamjanovicClinical Department for Renal Diseases, Zvezdara University Medical Center, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Nada DimkovicClinical Department for Renal Diseases, Zvezdara University Medical Center, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Rodoljub MarkovicDepartment of Nephrology and Hemodialysis, University Teaching Hospital Zemun, Belgrade, Serbia.
Ana Savic-RadojevicInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tatjana SimicInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RSZemun Hospital · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxidative stress in patients with end-stage renal disease (ESRD) is associated with long-term cardiovascular complications. The cytosolic family of glutathione S-transferases (GSTs) is involved in the detoxication of various toxic compounds and antioxidant protection. GST omega class members, GSTO1 and GSTO2 possess, unlike other GSTs, dehydroascorbate reductase and deglutathionylation activities. The aim of this study was to clarify the role of genetic polymorphisms of GSTO1 (rs4925) and GSTO2 (rs156697) as risk determinants for ESRD development, as well as in the survival of these patients.

methodsA total of 199 patients and 199 healthy subjects were included in the study and genotyped for both GSTO1 and GSTO2 polymorphism. Protein thiol and carbonyl groups as markers of protein oxidative damage were determined spectrophotometrically. Cox proportional hazard model and Kaplan-Meier analysis were performed to investigate the role of GSTO1 and GSTO2 genetic polymorphism on mortality of ESRD patients during the follow-up period (36 month).

resultsIndividuals carrying the variant

conclusionsGSTO polymorphisms have been shown to act as significant markers in assessing the risk of ESRD development and patients' survival.

Indexed as

end-stage renal diseasegenetic polymorphismglutathione S-transferaseoxidative stress

Identifiers

PMID28356881
PMCPMC5346808
OpenAlexW2472279240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.